One Strategy to Play the Hottest Sector in the Game

[Image] How Far Can Raptor 5 Take You? Your Only Limit Is... The Depth of Your Greed and Desire [Watch This]( Dear trader, Biotechs are taking the market by storm right now— The SPDR Biotech ETF (XBI) is sitting at 52-week highs. Yet most people trading biotechs right now are losing money… big money. The fact is there’s more incompetence in biotechs than any other industry. Most traders, and even most so-called market experts, wouldn’t know a good biotech setup if it bit them on the ass. That’s why we’re leaning on our resident biotech expert, Kyle Dennis, for this issue of All-Access. Kyle will be sharing the one biotech strategy that has put over a million bucks into his pocket over the past year. You’ll also receive the following tips from our pros: - [Jason Bond]( has a solution to your tariff-induced fears. Rather than worrying about unfavorable outcomes, you’ll learn how to ‘insure’ your stock positions. - [Jeff Williams]( discloses the three stocks on his radar— primed for a “short squeeze.” - [Jeff Bishop]( reveals the most effective way to “buy the rumor and sell the news” — and how it made him $71K in profits on BIIB. - [Ben Sturgill]( shares his list of 2019’s hottest brands. You’ll want to pay attention to these, as they could lead the pack in 2020. How far can Kyle’s Raptor 5 service take you? The only limit is the depth of your greed and desire. [Image]( Kyle only uses proven strategies. Raptor 5 puts in your hands the strategies and techniques Kyle applies to the market each day—the same ones responsible for over $7.5M in trading profits! The best thing is you don’t need to invest long hours or donate money to the market when you are equipped with these tools. [Watch Now]( [I'm an image] While the movement in the broader Health Care Sector SPDR Fund (XLV) has delivered a nice 15% year-to-date gains (as of Monday), the SPDR Biotech ETF (XBI) has returned 32% in the same time frame — more than double the amount of growth. The 52-week high that we saw in the XBI came after a whirlwind of new deals: - Merck bought cancer drugmaker, ArQule for $2.7B - Sanofi rounded up $2.5 billion in shares for control of Synthorx, a cancer and autoimmune disorder therapy company - Roche offered $4.3B to absorb Spark Therapeutics, a gene therapy innovator Drug companies are making tons of deals. And new therapies and treatments are being invented. And you know what else? Trading biotech stocks offers some of the most explosive opportunities in the entire market. You can just imagine the look on the face of our resident biotech expert, Kyle Dennis, as he says, “Make it rain, baby... make it rain!” Seriously, in the past month alone he’s taken 3 big winners in his biotech service alone — 25% on Sierra Oncology (SRRA), 28% on Verastem (VSTM), and 38% on DelMar Pharmaceuticals (DMPI). With biotechs, it’s not uncommon to (conservatively) see 20+ percent gains happen overnight — no wonder Kyle’s calling it the hottest sector in the game. But here’s the thing… while plenty of spokespeople out there in the media are trying to call tops and bottoms in the biotech market, Kyle knows that’s a fool's errand. So what is Kyle doing? He’s zooming in on opportunities by getting stock specific. He has a watchlist of specific catalysts that could prompt a violent (but very bullish) breakout. Once he identifies something interesting (based on his proven system), he looks for a promising setup where the risk vs. reward is heavily skewed in his favor. [Click here to join Raptor 5 and get the]([Kyle Dennis biotech trading experience.]( Make no mistake about it — healthcare and drug companies will be the center of attention as we approach the 2020 Presidential election. If you recall, during the last election, biotechs were super volatile — creating trading opportunities nearly every single day. What should you do to prepare? Simple. For a limited time, you can gain access to ALL of Kyle’s trading services at our best price ever. By signing up you’ll have the same trading tools that help Kyle squeeze out seven figures from the market. [Take advantage of this limited-time offer here.]( [I'm an image] [How to ‘Insure’ Profits Ahead of Possible Tariffs]( By Jason Bond of Weekly Windfalls [Image]( Traders are sitting on the edges of their seats in anticipation of an important date this week — the December 15 tariff deadline. Trump suggested last week that the compromise may not come until after the 2020 election, so brace yourself for a potential new round of tariffs. While the market could react badly to more tariffs — as it did the last time a new round of them were ushered in — Jason Bond has a strategy that could insure you against such an outcome. It’s called hedging, and it consists of protecting your shares with put options. Jason will explain to you exactly how it works. [Continue reading...]( [Eyeing a Short Squeeze]( By Jeff Williams of Penny Pro [Image]( In short… a short squeeze where an onslaught of short-sellers, all in a short period of time, close their orders and cause the price of a stock to rise dramatically. If you’re part of the short-selling action here, you better not be the last one holding the bag — you stand to lose everything. On the flip side, short squeezes are a fantastic opportunity to grab profits by going long on a stock. The very best market opportunity, in fact. In this post, Jeff Williams put together a watchlist of 3 stocks that are primed for a short squeeze. Jeff uses some charts to walk you through their recent price action and catalyst potential. [Continue reading...]( [Buy the Rumor, Sell the News]( By Jeff Bishop of Total Alpha [Image]( Buying the rumor and selling the news is a tried and true strategy. It has brought many traders tremendous profits over the years — like the $71K profits it brought Jeff Bishop when he played BIIB options recently. But there’s a right way and wrong way to trade the news. That’s because not all catalysts are created equal. In this post, he reflects on the difference between trading catalysts that are known events (earnings for example) versus ones that are probable (like biotechs releases). He’ll explain how to trade each of those scenarios and determine the best course for you. [Continue reading...]( [The Fastest Growing Brands of 2019]( By Ben Sturgill of IPO Payday [Image]( As we wrap up 2019, it’s fun to take a look back and determine what brands really influenced the year. Some of them progressed from ordinary and unknown companies into ones with huge, cult-like followings. One of them even caused widespread panic to hoard its products. In this post, Ben Sturgill reveals some of the hottest growing brands, some that could directly affect publicly-traded companies. He puts a spotlight on four of the most disruptive ones in particular. [Continue reading...]( To your success, The RagingBull.com Team RagingBull, LLC 62 Calef Hwy #233 Lee, New Hampshire 03861 United States [Stop receiving exclusive emails from Raging Bull All Access]( Neither Raging Bull nor RagingBull.com, LLC (publisher of Raging Bull) is registered as an investment adviser nor a broker/dealer with either the U. S. Securities & Exchange Commission or any state securities regulatory authority. Users of this website are advised that all information presented on this website is solely for informational purposes, is not intended to be used as a personalized investment recommendation, and is not attuned to any specific portfolio or to any user's particular investment needs or objectives. Past performance is NOT indicative of future results. Furthermore, such information is not to be construed as an offer to sell or the solicitation of an offer to buy, nor is it to be construed as a recommendation to buy, hold or sell (short or otherwise) any security. All users of this website must determine for themselves what specific investments to make or not make and are urged to consult with their own independent financial advisors with respect to any investment decision. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. All opinions, analyses and information included on this website are based on sources believed to be reliable and written in good faith, but should be independently verified, and no representation or warranty of any kind, express or implied, is made, including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. In addition, we undertake no responsibility to notify such opinions, analyses or information or to keep such opinions, analyses or information current. Also be aware that owners, employees and writers of and for RagingBull.com, LLC may have long or short positions in securities that may be discussed on this website or newsletter. Past results are not indicative of future profits. This table is accurate, though not every trade is represented. Profits and losses reported are actual figures from the portfolios Raging Bull manages on behalf of RagingBull.com, LLC. [Unsubscribe from all RagingBull Emails](